From Yahoo Finance: 2025-05-09 17:17:00

Recursion Pharmaceuticals suffered a 24% stock drop due to disappointing earnings and cutting development pipeline. The company reported a loss of $0.50 per share on $14.75 million in sales, slightly missing the $14.98 million forecast. A survey indicated that Trump’s actions may hinder biotech companies in raising capital. Recursion remains in the red and will need external funding to sustain operations. While the company’s AI research shows promise, uncertainty remains for investors. The Motley Fool did not recommend Recursion in their top 10 stocks. Stock Advisor has historically outperformed the S&P 500 with a 909% average return.



Read more at Yahoo Finance: Why Recursion Pharmaceuticals Stock Plummeted 24% This Week